Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib - Onyx Pharmaceuticals

Drug Profile

Carfilzomib - Onyx Pharmaceuticals

Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteolix
  • Developer Dana-Farber Cancer Institute; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Mantle-cell lymphoma; Prostate cancer; Renal cell carcinoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Solid tumours
  • No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 24 Oct 2018 Oncolytics Biotech and Emory University initiates enrolment in a phase I trial for Multiple-myeloma (Combination therapy, Second line therapy or greater) in USA (NCT03605719)
  • 01 Oct 2018 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Leukaemia(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top